Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + olodaterol versus tiotropium for COPD exacerbation reduction
NL-OMON44270Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tiotropium + olodaterol with Tiotropium (2 arms). Primary endpoint: Annualised rate of moderate to severe COPD exacerbation. Started Feb 2015; status: active, not recruiting.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON44270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44270.